Growth Analyser Growth Analyser

Compare funds

Pick up to 10 funds. Compare funds from the same category for a fair reading.

Nippon India Pharma Fund · Direct ✕Edelweiss Business Cycle Fund · Direct ✕

Growth of ₹10,000

Basics

Nippon India Pharma FundEdelweiss Business Cycle Fund
CategorySectoral / ThematicSectoral / Thematic
PlanDirectDirect
Fund houseNippon IndiaEdelweiss
NAV₹666.3420₹9.5446
NAV date20 Nov 202620 Nov 2026
History13.9 years2.3 years
Expense ratio1.0%1.2%
Stars★★★★★Not rated
Growth Score75.20—

Returns

Nippon India Pharma FundEdelweiss Business Cycle Fund
1 month+11.40%+5.85%
3 months+3.74%+1.17%
6 months+8.55%+5.73%
YTD+16.94%+3.05%
1 year+15.26%+3.75%
3 years (CAGR)+17.96%—
5 years (CAGR)+15.40%—
10 years (CAGR)+16.61%—
Since launch+17.63%−2.21%

Risk

Nippon India Pharma FundEdelweiss Business Cycle Fund
Volatility14.1%—
Downside volatility9.0%—
Sharpe0.81—
Sortino1.28—
Calmar1.22—
Return / risk1.27—
Deepest fall−24.02%−26.39%
Days to recover445—
Below its high+0.00%−7.61%

Against benchmark

Nippon India Pharma FundEdelweiss Business Cycle Fund
Alpha−1.86%—
Beta0.89—
R²89.5%—
Up capture85.2%—
Down capture88.7%—
Tracking error4.8%—
Information ratio−0.69—
Treynor0.12—

Consistency

Nippon India Pharma FundEdelweiss Business Cycle Fund
Best 1-year+90.70%+20.97%
Middle 1-year+13.13%+1.01%
Worst 1-year−15.12%−14.64%
1-year periods with a loss23.2%43.9%
Middle 3-year+19.82%—
Positive months63.9%—
Best day+3.40%+4.77%
Worst day−3.21%−3.85%
Worst 5% day−1.38%−2.02%
Positive days53.7%54.0%
NAVs a year247247

SIP of ₹10,000 a month

Nippon India Pharma FundEdelweiss Business Cycle Fund
5-year XIRR+18.24%—
5-year value₹9,54,076—
3-year XIRR+14.26%—
1-year XIRR+22.08%+9.07%

Holdings overlap i

Overlap needs the monthly portfolio filing of at least two of these funds; not loaded yet.

Search Growth